ELTD1—An Emerging Silent Actor in Cancer Drama Play

Abstract

The epidermal growth factor, latrophilin, and seven transmembrane domain–containing protein 1 (ELTD1), is a member of the G–protein coupled receptors (GPCRs) superfamily. Although discovered in 2001, ELTD1 has been investigated only by a few research groups, and important data about its role in normal and tumor cells is still missing. Even though its functions and structure are not yet fully understood, recent studies show that ELTD1 has a role in both physiological and pathological angiogenesis, and it appears to be a very important biomarker and a molecular target in cancer diseases. Upregulation of ELTD1 in malignant cells has been reported, and correlated with poor cancer prognosis. This review article aims to compile the existing data and to discuss the current knowledge on ELTD1 structure and signaling, and its role in physiological and neoplastic conditions.

ELTD1 Promotes Gastric Cancer Cell Proliferation, Invasion and Epithelial–Mesenchymal Transition Through MAPK/ERK Signaling by Regulating CSK

“…The cytoplasmic domain of ELTD1 composes a tyrosine kinase phosphorylation site, indicating ELTD1 may involve in intracellular signaling. 27 Unfortunately, little information is available at present on the potential downstream signaling pathways related to ELTD1. 28 In glioma cells, ELTD1 overexpression could promote HIF-1α protein expression by activating JAK/STAT3 signaling pathway.…”

Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy

“…Tumor cells create new vessels from existing ones by liberating various factors that induce angiogenesis in a direct or indirect manner (angiogenic switch), followed by extracellular matrix degradation and endothelial migration. There are many signaling pathways, mediators, and downstream signaling proteins reported in angiogenesis-induced cancer: platelet-derived growth factor (PDGF), VEGF, fibroblast growth factors (FGF), hepatocyte growth factor (HGF), TKs, PI3K, MAPK, mTOR, Ras, and Raf [ 71 , 141 , 142 , 143 , 144 ].…”

The effect of Azo-dyes on glioblastoma cells in vitro

“…By adding of bevacizumab to standard treatment, progression-free survival (PFS) has been improved, but no increase in overall survival (OS) and higher adverse events rate have been observed ( Chinot et al, 2014 ). Furthermore, significant advances have been made by using: targeted therapy ( Alexandru et al, 2015 , Artene et al, 2018 , Sevastre et al, 2019 , Sevastre et al, 2021a ), cell therapy ( Alexandru et al, 2015 , Artene et al, 2018 , Sevastre et al, 2021a ), ablation therapy ( Debela et al, 2021 ), nanoparticles ( Sevastre et al, 2019 ), radionics, chemo- and sono-dynamic therapy ( Debela et al, 2021 ).…”